Embryo Quality May Be Associated With Serum Inhibin B Levels but Not With Serum or Follicular Fluid Levels of Other Components of the Activin-Follistatin-Inhibin Axis.


Journal

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
ISSN: 1530-891X
Titre abrégé: Endocr Pract
Pays: United States
ID NLM: 9607439

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 01 03 2022
revised: 30 07 2022
accepted: 02 08 2022
pubmed: 10 8 2022
medline: 13 10 2022
entrez: 9 8 2022
Statut: ppublish

Résumé

We investigated the potential associations of embryo quality with serum and/or follicular fluid (FF) concentrations of the molecules of the activin-follistatin-inhibin (AFI) axis and antimüllerian hormone and aimed to identify molecules that could predict a positive assisted reproductive technology (ART) outcome. In this cross-sectional study, we measured AFI hormone and antimüllerian hormone levels in the serum and FF of follicles (n = 101) obtained from healthy oocyte donors who underwent an assisted reproductive technology course (n = 32). After egg retrieval, embryos were characterized as good or bad quality according to the European Society of Human Reproduction and Embryology criteria. Women were divided into 3 groups (<50%; 50%-66.7%; and >66.7%) according to the percentage of good quality embryos obtained. There was no difference between good and bad quality embryos in any of the molecules measured in FF. Moreover, there was no difference in the parameters measured in the serum among women according to the percentage of good quality embryos (ie, suitable for transfer or freezing) except for inhibin B, which tended to increase along with a good quality embryo rate (55.6 ± 7.9 vs 95.3 ± 14.3 vs 113.9 ± 36.9; P = .045). Among the molecules of the AFI axis, only serum but not FF inhibin B levels were marginally associated with good quality embryo rates.

Identifiants

pubmed: 35944841
pii: S1530-891X(22)00577-8
doi: 10.1016/j.eprac.2022.08.001
pii:
doi:

Substances chimiques

Follistatin 0
inhibin B 0
Activins 104625-48-1
Inhibins 57285-09-3
Anti-Mullerian Hormone 80497-65-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1086-1090

Informations de copyright

Published by Elsevier Inc.

Auteurs

Eirini Bouzoni (E)

Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts.

Eleftherios Gavriil (E)

Newlife IVF Clinic, Thessaloniki, Greece.

Athanasios D Anastasilakis (AD)

Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece.

Dimitrios Dovas (D)

Newlife IVF Clinic, Thessaloniki, Greece.

Aditya Joshi (A)

Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts.

Despina D Briana (DD)

Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital Attikon, Athens, Greece.

Christos S Mantzoros (CS)

Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts; Section of Endocrinology, VA Boston Healthcare System, Jamaica Plain, Massachusetts. Electronic address: cmantzor@bidmc.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH